Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02017249 · ClinicalTrials.gov registry record · Phase 1
Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme
A Phase 1 study, sponsored by Inova Health Care Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02017249: Completed Phase 1 study, sponsored by Inova Health Care Services.
NCT02017249 is a Phase 1 study that has completed, run by Inova Health Care Services. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02017249, a Phase 1 study, has completed, sponsored by Inova Health Care Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about the ability of a substance called arginine to improve the functioning of the immune system in people with a certain type of brain tumor. This could lead to improvements in a type of treatment for brain tumors called immunotherapy. The immune system includes organs, cells, and substances in the body that fight infection and disease. Immunotherapy is a type of treatment that uses the immune system as a tool to seek out and destroy abnormal cells. Immunotherapy requires that the immune system be working properly. Arginine is a normal component of protein (an amino acid) that we all consume in foods such as red meat, poultry, fish, and dairy products and that our bodies can make. Arginine helps the immune system function normally. Recent research has shown that certain types of brain tumors decrease the amount of arginine in the body leading to impaired immune system function. This may interfere with the ability of immunotherapy to fight abnormal cells. We would like to see if giving people with brain tumors arginine in powder form will make their immune systems work better.
Primary Outcome
25% increase in the functional response of peripheral T cells
Interventions
- DRUG arginine in powder form
- DRUG Silica and cellulose placebo powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-10-06 |
| Phase | Phase 1 |
What the finished NCT02017249 record still lists
NCT02017249 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which arginine in powder form is the first listed.
NCT02017249 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02017249 about?
NCT02017249 is a clinical study titled "Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme". The purpose of this study is to learn more about the ability of a substance called arginine to improve the functioning of the immune system in people with a certain type of brain tumor. This could lead to improvements in a type of treatment for brain tumors called immunotherapy. The immune system in...
What is the current status of trial NCT02017249?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2014-03. Estimated completion is 2015-10-06.
What interventions are being tested in trial NCT02017249?
The interventions under investigation include: arginine in powder form (DRUG), Silica and cellulose placebo powder (DRUG).
Who is sponsoring clinical trial NCT02017249?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02017249's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia